Jonathan J H Bray, Marco Coronelli, Sam G C Scott, John A Henry, Liam S Couch, Mahmood Ahmad, Julian Ormerod, James Gamble, Timothy R Betts, Andrew Lewis, Oliver J Rider, Peregrine G Green, Neil Herring
AIMS: The trials upon which recommendations for the use of cardiac resynchronization therapy (CRT) in heart failure used optimal medical therapy (OMT) before sodium-glucose co-transporter 2 inhibitors (SGLT2i). Moreover, the SGLT2i heart failure trials included only a small proportion of participants with CRT, and therefore, it remains uncertain whether SGLT2i should be considered part of OMT prior to CRT. METHODS AND RESULTS: We compared electrocardiogram (ECG) and echocardiographic responses to CRT as well as hospitalization and mortality rates in consecutive patients undergoing implantation at a large tertiary centre between January 2019 to June 2022 with and without SGLT2i treatment...
April 22, 2024: ESC Heart Failure